BRPI1011404B1 - Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira - Google Patents

Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira Download PDF

Info

Publication number
BRPI1011404B1
BRPI1011404B1 BRPI1011404-1A BRPI1011404A BRPI1011404B1 BR PI1011404 B1 BRPI1011404 B1 BR PI1011404B1 BR PI1011404 A BRPI1011404 A BR PI1011404A BR PI1011404 B1 BRPI1011404 B1 BR PI1011404B1
Authority
BR
Brazil
Prior art keywords
fgf21
seq
polypeptide
mutants
mutant
Prior art date
Application number
BRPI1011404-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Edward John Belouski
Murielle Marie Ellison
Agnes Eva Hamburger
Randy Ira Hecht
Yue-Sheng Li
Mark Leo Michaels
Jeonghoon Sun
Jing Xu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42455356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1011404(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of BRPI1011404A2 publication Critical patent/BRPI1011404A2/pt
Publication of BRPI1011404B1 publication Critical patent/BRPI1011404B1/pt

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Child & Adolescent Psychology (AREA)
BRPI1011404-1A 2009-05-05 2010-05-04 Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira BRPI1011404B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17573609P 2009-05-05 2009-05-05
US61/175,736 2009-05-05
US28511809P 2009-12-09 2009-12-09
US61/285,118 2009-12-09
PCT/US2010/033478 WO2010129503A1 (en) 2009-05-05 2010-05-04 Fgf21 mutants and uses thereof

Publications (2)

Publication Number Publication Date
BRPI1011404A2 BRPI1011404A2 (pt) 2016-03-15
BRPI1011404B1 true BRPI1011404B1 (pt) 2022-05-03

Family

ID=42455356

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1011404-1A BRPI1011404B1 (pt) 2009-05-05 2010-05-04 Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira

Country Status (37)

Country Link
US (4) US8188040B2 (cg-RX-API-DMAC7.html)
EP (3) EP4353247A3 (cg-RX-API-DMAC7.html)
JP (1) JP5823954B2 (cg-RX-API-DMAC7.html)
KR (2) KR20180014235A (cg-RX-API-DMAC7.html)
CN (2) CN102655877B (cg-RX-API-DMAC7.html)
AR (1) AR076541A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010246108B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1011404B1 (cg-RX-API-DMAC7.html)
CA (1) CA2760196C (cg-RX-API-DMAC7.html)
CL (1) CL2011002768A1 (cg-RX-API-DMAC7.html)
CO (1) CO6470863A2 (cg-RX-API-DMAC7.html)
CR (1) CR20110639A (cg-RX-API-DMAC7.html)
DK (1) DK3248610T5 (cg-RX-API-DMAC7.html)
EA (1) EA021425B1 (cg-RX-API-DMAC7.html)
ES (2) ES2969528T3 (cg-RX-API-DMAC7.html)
FI (1) FI3248610T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240135T1 (cg-RX-API-DMAC7.html)
HU (1) HUE065036T2 (cg-RX-API-DMAC7.html)
IL (2) IL215937A (cg-RX-API-DMAC7.html)
JO (1) JO3469B1 (cg-RX-API-DMAC7.html)
LT (1) LT3248610T (cg-RX-API-DMAC7.html)
MA (1) MA33716B1 (cg-RX-API-DMAC7.html)
MX (1) MX2011011709A (cg-RX-API-DMAC7.html)
MY (1) MY156542A (cg-RX-API-DMAC7.html)
NZ (1) NZ596037A (cg-RX-API-DMAC7.html)
PE (2) PE20160718A1 (cg-RX-API-DMAC7.html)
PH (1) PH12015502433B1 (cg-RX-API-DMAC7.html)
PL (1) PL3248610T3 (cg-RX-API-DMAC7.html)
PT (1) PT3248610T (cg-RX-API-DMAC7.html)
RS (1) RS65153B1 (cg-RX-API-DMAC7.html)
SG (3) SG10201707763PA (cg-RX-API-DMAC7.html)
SI (1) SI3248610T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400036T1 (cg-RX-API-DMAC7.html)
TW (2) TWI560197B (cg-RX-API-DMAC7.html)
UY (2) UY38740A (cg-RX-API-DMAC7.html)
WO (1) WO2010129503A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201108371B (cg-RX-API-DMAC7.html)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
SG195542A1 (en) 2008-10-10 2013-12-30 Amgen Inc Fgf21 mutants and uses thereof
UY38740A (es) 2009-05-05 2020-12-31 Amgen Inc Mutantes de fgf21 y usos del mismo
JP2012525847A (ja) * 2009-05-05 2012-10-25 アムジエン・インコーポレーテツド Ｆｇｆ２１変異体およびその使用
AU2010262927A1 (en) 2009-06-17 2012-01-19 Amgen Inc. Chimeric FGF19 polypeptides and uses thereof
AU2010326024A1 (en) 2009-12-02 2012-07-05 Amgen Inc. Binding proteins that bind to human FGFR1c, human beta-Klotho and both human FGFR1c and human beta-Klotho
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
AU2011239689A1 (en) 2010-04-15 2012-11-08 Amgen Inc. Human FGF receptor and beta-Klotho binding proteins
JP5767314B2 (ja) 2010-04-16 2015-08-19 ソーク インスティチュート フォー バイオロジカル スタディーズ Ｆｇｆを用いて代謝障害を処置するための方法
CA2835101A1 (en) * 2011-05-10 2012-11-15 Amgen Inc. Method of identifying compounds that specifically modulate the interaction of fgfr1 and .beta.-klotho
US8951966B2 (en) 2011-07-01 2015-02-10 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
WO2013033452A2 (en) 2011-08-31 2013-03-07 Amgen Inc. Method of treating or ameliorating type 1 diabetes using fgf21
TW201315742A (zh) * 2011-09-26 2013-04-16 Novartis Ag 治療代謝病症之雙功能蛋白質
US9006400B2 (en) * 2011-09-26 2015-04-14 Novartis Ag Fibroblast growth factor-21-Fc fusion proteins
AU2015202304C1 (en) * 2011-09-26 2017-03-09 Novartis Ag Fusion proteins for treating metabolic disorders
AR087973A1 (es) 2011-10-04 2014-04-30 Lilly Co Eli Variantes del factor 21 del crecimiento de fibroblastos
US9475856B2 (en) 2012-03-02 2016-10-25 New York University Chimeric FGF21 proteins with enhanced binding affinity for β-klotho for the treatment of type II diabetes, obesity, and related metabolic disorders
JP6254146B2 (ja) 2012-03-27 2017-12-27 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 代謝障害を治療するための組成物および方法
KR20220051197A (ko) 2012-05-17 2022-04-26 익스텐드 바이오사이언시즈, 인크. 개선된 약물 전달용 캐리어
US9474785B2 (en) 2012-06-07 2016-10-25 New York University Chimeric fibroblast growth factor 19 proteins and methods of use
US9464126B2 (en) 2012-06-07 2016-10-11 New York University Chimeric fibroblast growth factor 21 proteins and methods of use
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
WO2013188182A1 (en) 2012-06-11 2013-12-19 Eli Lilly And Company Fibroblast growth factor 21 variants
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
WO2014085365A2 (en) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
DK2938740T3 (da) 2012-12-27 2022-06-20 Ngm Biopharmaceuticals Inc Kimære fgf19-peptider til anvendelse til behandling af galdesyrelidelser
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
EP2950807B1 (en) * 2013-01-30 2018-03-28 NGM Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
US9550820B2 (en) 2013-02-22 2017-01-24 New York University Chimeric fibroblast growth factor 23/fibroblast growth factor 19 proteins and methods of use
WO2014149699A1 (en) 2013-03-15 2014-09-25 Eli Lilly And Company Bifunctional protein
WO2015057908A1 (en) 2013-10-18 2015-04-23 Novartis Ag Methods of treating diabetes and related disorders
CN105828833A (zh) 2013-10-21 2016-08-03 萨克生物研究学院 突变的成纤维细胞生长因子（fgf）1及使用方法
WO2015065897A1 (en) 2013-10-28 2015-05-07 Ngm Biopharmaceuticals, Inc. Cancer models and associated methods
CN106662577B (zh) 2014-01-24 2020-07-21 恩格姆生物制药公司 结合蛋白及其使用方法
JP6712230B2 (ja) 2014-03-11 2020-06-17 ノバルティス アーゲー リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法
WO2015148708A1 (en) 2014-03-25 2015-10-01 Regeneron Pharmaceuticals, Inc. Fgf21 receptor agonists and uses thereof
CN103923207B (zh) * 2014-04-08 2016-03-09 东北农业大学 一种fgf-21突变体蛋白的制备及其在治疗非酒精性脂肪肝中的应用
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
MY192917A (en) 2014-07-30 2022-09-15 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
WO2016065106A1 (en) 2014-10-23 2016-04-28 Ngm Biopharmaceuticals, Inc. Pharmaceutical compositions comprising peptide variants and methods of use thereof
US9920118B2 (en) 2014-10-31 2018-03-20 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
HK1246156B (en) 2014-12-23 2020-03-27 Novo Nordisk A/S FGF21 derivatives and their uses
KR20160088656A (ko) 2015-01-16 2016-07-26 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
US20180071981A1 (en) * 2015-03-31 2018-03-15 The Regents Of The University Of California System and method for tunable patterning and assembly of particles via acoustophoresis
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
EP3331914A1 (en) 2015-08-03 2018-06-13 Novartis AG Methods of treating fgf21-associated disorders
JP2018529729A (ja) * 2015-10-01 2018-10-11 アムジエン・インコーポレーテツド 胆汁酸障害の処置
KR102670157B1 (ko) * 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
KR102668200B1 (ko) * 2015-10-28 2024-05-23 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
CA3002400A1 (en) 2015-10-30 2017-05-04 Salk Institute For Biological Studies Treatment of steroid-induced hyperglycemia with fibroblast growth factor (fgf) 1 analogs
WO2017083276A1 (en) 2015-11-09 2017-05-18 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
TW201731867A (zh) * 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
CA3016035A1 (en) 2016-03-31 2017-10-05 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
CN107759696A (zh) 2016-08-19 2018-03-06 安源医药科技（上海）有限公司 人白介素7融合蛋白及其制备方法
US11123438B2 (en) 2016-08-19 2021-09-21 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN109689079A (zh) * 2016-08-22 2019-04-26 伊兰科美国公司 牛成纤维细胞生长因子21和乳畜中的酮病
CA3034399A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
BR112019009581A2 (pt) * 2016-11-10 2019-10-08 Yuhan Corp composição farmacêutica para evitar ou tratar hepatite, fibrose hepática, e cirrose hepática que compreende proteínas de fusão
CN110087671A (zh) 2016-12-22 2019-08-02 赛诺菲 具有优化的活性比率的fgf21化合物/glp-1r激动剂组合
WO2018166461A1 (en) 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
MX2019012331A (es) 2017-04-21 2020-01-23 Yuhan Corp Metodo para producir proteinas de doble funcion y sus derivados.
CN107056925B (zh) * 2017-04-28 2022-01-14 中国科学院合肥物质科学研究院 人fgf21突变体、其制备方法及用途
KR102399458B1 (ko) * 2017-10-27 2022-05-17 사바 라이프 사이언스 에이비 면역-분석 플랫폼들 상 분석을 위한 세포-기반의 분석들을 최적화하기 위한 분비된 리포터-펩타이드들
RS65720B1 (sr) 2017-12-22 2024-08-30 Novartis Ag Tretiranje metaboličkih poremećaja pomoću fgf21 varijanti
EP3749683A4 (en) * 2018-02-08 2022-03-16 Sunshine Lake Pharma Co., Ltd. FGF21 VARIANT, FUSION PROTEIN AND USE THEREOF
EP3586860A1 (en) * 2018-06-22 2020-01-01 Universität Ulm Complement inhibitors and uses thereof
BR112020026512A2 (pt) 2018-07-03 2021-04-06 Bristol-Myers Squibb Company Formulações de fgf-21
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途
CA3123325A1 (en) * 2019-03-05 2020-09-10 Sunshine Lake Pharma Co., Ltd. A polypeptide molecule and application thereof
CN114853908B (zh) 2019-05-16 2024-06-07 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
US11542309B2 (en) 2019-07-31 2023-01-03 Salk Institute For Biological Studies Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
KR102495299B1 (ko) * 2020-11-03 2023-02-06 토드제약 주식회사 Fgf21의 열탄력성을 이용한 fgf21 생산 방법
EP4308610A4 (en) * 2021-03-19 2025-07-16 Sunshine Lake Pharma Co Ltd USES OF FGF21 POLYPEPTIDES AND FUSION POLYPEPTIDES THEREOF
CN113583142A (zh) * 2021-08-20 2021-11-02 赣江中药创新中心 双靶点融合蛋白、编码基因、载体或宿主细胞及其应用与表达和纯化方法
CN116162145A (zh) * 2021-09-08 2023-05-26 北京志道生物科技有限公司 一种fgf21突变蛋白及其应用
EP4406968A4 (en) 2021-09-23 2025-03-12 Jiangsu Hengrui Pharmaceuticals Co., Ltd. ANTI-KLB ANTIBODIES AND USES
JP2024538158A (ja) 2021-10-13 2024-10-18 アケロ セラピューティクス，インコーポレイティド エフルキシフェルミンの薬学的組成物
JP2025531878A (ja) 2022-09-12 2025-09-25 アケロ セラピューティクス，インコーポレイティド Ｆｇｆ２１変異体ポリペプチド
JP2025534350A (ja) 2022-09-30 2025-10-15 エクステンド バイオサイエンシズ インコーポレーテッド 長時間作用型副甲状腺ホルモン
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
CN118496383B (zh) * 2023-06-02 2025-10-31 东北农业大学 犬成纤维细胞生长因子21融合蛋白制备及其在治疗特应性皮炎中的用途
WO2025155843A1 (en) 2024-01-19 2025-07-24 Akero Therapeutics, Inc. Method of treating liver or lung injury

Family Cites Families (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
DE3675588D1 (de) * 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
CA1310924C (en) * 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4970154A (en) * 1987-10-09 1990-11-13 Baylor College Of Medicine Method for inserting foreign genes into cells using pulsed radiofrequency
EP0315456B1 (en) 1987-11-05 1994-06-01 Hybritech Incorporated Polysaccharide-modified immunoglobulins having reduced immunogenic potential or improved pharmacokinetics
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5106627A (en) * 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5011472A (en) * 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5288855A (en) * 1989-01-23 1994-02-22 Farmitalia Carlo Erba Extracellular form of the human fibroblast growth factor receptor
AU638734B2 (en) * 1989-07-06 1993-07-08 Regents Of The University Of California, The Receptors for fibroblast growth factors
US5676954A (en) * 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
CA2071989C (en) 1989-12-22 1999-07-27 Scott C. Chappel Endogenous gene expression modification with regulatory element
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
WO1991010470A1 (en) 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5672510A (en) * 1990-01-19 1997-09-30 Genetic Therapy, Inc. Retroviral vectors
CA2086425C (en) 1990-07-06 2006-01-17 Craig A. Dionne Fibroblast growth factor receptors
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5217889A (en) * 1990-10-19 1993-06-08 Roninson Igor B Methods and applications for efficient genetic suppressor elements
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5229501A (en) * 1991-01-11 1993-07-20 Chiron Corporation Expression and use of human fibroblast growth factor receptor
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
IL100219A0 (en) 1991-12-02 1992-09-06 Yeda Res & Dev Variable region within fibroblast growth factor receptors that confers ligand specificity
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US5364791A (en) * 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
DK0646182T3 (da) * 1992-06-18 1996-09-16 Whittier Inst Diabetes & Endoc Fremgangsmåde til påvisning af neoplastiske sygdomme
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US5474914A (en) 1992-07-29 1995-12-12 Chiron Corporation Method of producing secreted CMV glycoprotein H
US5489743A (en) 1993-01-19 1996-02-06 Amgen Inc. Transgenic animal models for thrombocytopenia
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
GB9313210D0 (en) * 1993-06-25 1993-08-11 Sandoz Ltd Novel combinations
WO1994028122A1 (en) 1993-05-26 1994-12-08 Ontario Cancer Institute Transgenic mammals lacking expression of particular cd45 isoforms
US6664107B1 (en) * 1993-05-26 2003-12-16 Ontario Cancer Institute, University Health Network CD45 disrupted nucleic acid
US5589362A (en) 1993-06-14 1996-12-31 Basf Aktiengesellschaft Tetracycline regulated transcriptional modulators with altered DNA binding specificities
US5654168A (en) 1994-07-01 1997-08-05 Basf Aktiengesellschaft Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units
AU684524B2 (en) * 1993-06-14 1997-12-18 Tet Systems Holding Gmbh & Co. Kg Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5469743A (en) * 1993-06-24 1995-11-28 Zorn; Roger H. Dynamic surface wave roll inspection device
EP1179350A3 (en) 1993-08-12 2003-01-02 Cytotherapeutics, Inc. Encapsulated cell system for implantation into the human CNS
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5484720A (en) * 1994-09-08 1996-01-16 Genentech, Inc. Methods for calcium phosphate transfection
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5654166A (en) * 1994-11-09 1997-08-05 Kurth; Gerhard P. Process of preparing hormone-free bovine cartilage for dosage form
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
WO1996037609A1 (en) 1995-05-26 1996-11-28 Zeneca Limited A gene switch comprising an ecdysone receptor
US5849303A (en) 1995-06-07 1998-12-15 American Home Products Corporation Recombinant feline Immunodeficiency virus subunit vaccines employing baculoviral-expressed envelope glycoproteins derived from isolate NCSU-1 and their use against feline immunodeficiency virus infection
EP0832269A1 (en) 1995-06-07 1998-04-01 Baylor College Of Medicine Nucleic acid transporters for delivery of nucleic acids into a cell
WO1996041865A1 (en) 1995-06-07 1996-12-27 Ariad Gene Therapeutics, Inc. Rapamcycin-based regulation of biological events
AU2192797A (en) 1996-02-28 1997-09-16 Ariad Gene Therapeutics, Inc. Synthetic derivatives of rapamycin as multimerising agents for chimeric proteins with immunophilin derived domains
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US5679559A (en) * 1996-07-03 1997-10-21 University Of Utah Research Foundation Cationic polymer and lipoprotein-containing system for gene delivery
US6214795B1 (en) * 1996-11-12 2001-04-10 Praecis Pharmaceuticals, Inc. Peptide compounds useful for modulating FGF receptor activity
KR20000062345A (ko) * 1996-12-26 2000-10-25 히라타 다다시 신규 폴리펩타이드, 신규 ｄｎａ 및 신규 항체
US6133426A (en) * 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
EP0861900A1 (en) * 1997-02-21 1998-09-02 Erziehungsdirektion Of The Canton Zurich Immunological detection of prions
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6150096A (en) * 1997-09-26 2000-11-21 Universite De Sherbrooke Molecular markers for the diagnosis of human diseases including Crohn's disease
AU733222B2 (en) 1997-11-25 2001-05-10 Genentech Inc. Fibroblast growth factor-19
US6150098A (en) 1998-02-20 2000-11-21 Amgen Inc. Methods for identifying novel secreted mammalian polypeptides
ZA200007412B (en) 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US6548634B1 (en) 1998-09-30 2003-04-15 Chiron Corporation Synthetic peptides having FGF receptor affinity
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2000027885A1 (en) 1998-11-05 2000-05-18 Kyowa Hakko Kogyo Co., Ltd. Novel chimeric polypeptide
WO2000046380A2 (en) 1999-02-08 2000-08-10 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
WO2000054813A2 (en) 1999-03-15 2000-09-21 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
CA2311201A1 (en) * 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins
US7408047B1 (en) * 1999-09-07 2008-08-05 Amgen Inc. Fibroblast growth factor-like polypeptides
US7459540B1 (en) * 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
WO2001018209A1 (en) 1999-09-10 2001-03-15 Curagen Corporation Fibroblast growth factor polypeptide and nucleic acids encoding same
WO2001032678A1 (en) * 1999-11-05 2001-05-10 Smithkline Beecham Corporation sbgFGF-19a
US6716626B1 (en) * 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
AU1922101A (en) * 1999-11-18 2001-05-30 Chiron Corporation Human fgf-21 gene and gene expression products
WO2001038357A2 (en) 1999-11-22 2001-05-31 Millennium Pharmaceuticals, Inc. Jaffa, a novel fibroblast growth factor family member and uses therefor
US7108984B2 (en) * 2000-01-12 2006-09-19 Mount Sinai School Of Medicine Methods of identifying modulators of the FGF receptor
AU2631001A (en) 2000-01-05 2001-07-16 Zymogenetics Inc. Novel fgf homolog zfgf11
US20020081663A1 (en) * 2000-01-05 2002-06-27 Conklin Darrell C. Novel FGF homolog ZFGF11
AU5056501A (en) 2000-03-31 2001-10-08 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
JP2002112772A (ja) 2000-07-10 2002-04-16 Takeda Chem Ind Ltd 新規ポリペプチドおよびそのｄｎａ
IL139380A0 (en) 2000-10-31 2001-11-25 Prochon Biotech Ltd Active variants of fibroblast growth factor
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US20060223114A1 (en) * 2001-04-26 2006-10-05 Avidia Research Institute Protein scaffolds and uses thereof
US20040018499A1 (en) * 2001-06-06 2004-01-29 Lal Preeti G Extracellular messengers
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
NZ530545A (en) * 2001-07-11 2006-10-27 Maxygen Holdings Ltd Specific conjugates comprising a polypeptide exhibiting G-CSF activity and a non-polypeptide moiety
WO2003011213A2 (en) 2001-07-30 2003-02-13 Eli Lilly And Company Method for treating diabetes and obesity
US20050187150A1 (en) * 2001-10-31 2005-08-25 New York University Structure-based design and synthesis of FGF inhibitors and FGF modulator compounds
JP2005519891A (ja) 2002-01-15 2005-07-07 イーライ・リリー・アンド・カンパニー 危篤状態の患者における罹病率および死亡率を低下させる方法
EP1332761A1 (en) * 2002-01-31 2003-08-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Agonists of fibroblast growth factor receptors (FGFR)
WO2003063893A2 (en) * 2002-01-31 2003-08-07 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Fgfr agonists
IL149562A0 (en) * 2002-05-09 2002-11-10 Prochon Ltd Fgf variants and methods for use thereof
JP2003334088A (ja) 2002-05-22 2003-11-25 Pharma Design Inc ヒト由来の新規Ｋｌｏｔｈｏ様タンパク質及びその遺伝子
AU2003265057A1 (en) 2002-09-04 2004-03-29 Abtech Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy
CA2503390A1 (en) 2002-11-01 2004-05-21 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
AU2003287918A1 (en) 2002-12-20 2004-07-14 Enkam Pharmaceuticals A/S Method of modulation of interaction between receptor and ligand
TWI300430B (en) * 2003-01-10 2008-09-01 Ritek Corp Optical recording medium dye and optical recording medium using thereof
MXPA04012390A (es) * 2003-01-23 2005-02-25 Lg Electronics Inc Medio de registro con informacion de proteccion contra duplicacion formada en cavidades modulada intermitentes o alternas y aparato y metodos para formar, registrar y reproducir el medio de registro.
WO2004083381A2 (en) 2003-03-13 2004-09-30 Indiana University Advanced Research & Technology Institute Fibroblast growth factor receptor-1 polynucleotides, polypeptides, and mutants
JP2006240990A (ja) 2003-05-15 2006-09-14 Kirin Brewery Co Ltd ｋｌｏｔｈｏタンパク質および抗ｋｌｏｔｈｏタンパク質抗体ならびにそれらの用途
UA87458C2 (ru) * 2003-06-12 2009-07-27 Елі Ліллі Енд Компані Гибридные белки-аналоги glp-1
SI1641483T1 (sl) 2003-06-12 2008-08-31 Lilly Co Eli Fuzijski proteini
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
DE602004032370D1 (de) 2003-10-16 2011-06-01 Imclone Llc Fibroblasten-wachstumsfaktor-1-hemmer und behandlungsverfahren dafür
BRPI0416683A (pt) * 2003-12-10 2007-01-30 Lilly Co Eli muteìna de fator de crescimento de fibroblasto de humano 21 (fgf-21), ou um seu peptìdeo biologicamente ativo, polinucleotìdeo, vetor de expressão, célula hospedeira, processo para produzir um polipeptìdeo, composição farmacêutica, método para tratar um paciente, e, uso da muteìna fgf-21
US20070248605A1 (en) 2003-12-19 2007-10-25 Five Prime Therapetutics, Inc. Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention
WO2005072769A1 (en) 2004-01-26 2005-08-11 Eli Lilly And Company Use of fgf-21 and thiazolidinedione for treating type 2 diabetes
US7887790B2 (en) * 2004-02-20 2011-02-15 Cornell Research Foundation, Inc. Polymers and polymer coatings
CA2557782A1 (en) * 2004-03-17 2005-10-06 Eli Lilly And Company Glycol linked fgf-21 compounds
JP4505631B2 (ja) * 2004-03-31 2010-07-21 独立行政法人産業技術総合研究所 ヘパラン硫酸糖鎖を付加したヘパリン結合性タンパク質、その製造方法及びそれを含有する医薬組成物
DE602005016917D1 (de) * 2004-05-13 2009-11-12 Lilly Co Eli Fgf-21-fusionsproteine
WO2006028714A1 (en) 2004-09-02 2006-03-16 Eli Lilly And Company Muteins of fibroblast growth factor 21
EA011390B1 (ru) * 2004-09-02 2009-02-27 Эли Лилли Энд Компани Мутантные белки (мутеины) фактора роста фибробластов 21
ES2566670T3 (es) 2004-10-29 2016-04-14 Ratiopharm Gmbh Remodelación y glucopegilación del factor de crecimiento de fibroblastos (FGF)
JP2008522617A (ja) * 2004-12-14 2008-07-03 イーライ リリー アンド カンパニー 線維芽細胞成長因子２１の突然変異タンパク質
WO2006078463A2 (en) 2005-01-21 2006-07-27 Eli Lilly And Company Method for treating cardiovascular disease
JP2006246823A (ja) 2005-03-11 2006-09-21 Kyoto Univ 造血因子としてのＦｇｆ２１の使用
WO2006130527A2 (en) 2005-05-31 2006-12-07 Novartis Ag Mutations and polymorphisms of fibroblast growth factor receptor 1
CA2614039C (en) * 2005-07-22 2015-10-13 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
EP1995321A2 (en) 2005-08-15 2008-11-26 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
US7395962B2 (en) 2005-10-28 2008-07-08 United Parcel Service Of America, Inc. Pick up notice and method of using same
US8043833B2 (en) 2005-10-31 2011-10-25 Novo Nordisk A/S Expression of soluble therapeutic proteins
US20110191871A1 (en) 2006-02-28 2011-08-04 Trustees Of Boston University Methods to identify factors associated with muscle growth and uses thereof
CA2655504A1 (en) 2006-06-15 2007-12-21 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
US9187532B2 (en) * 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
WO2008057683A2 (en) * 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
JP2010511382A (ja) * 2006-12-01 2010-04-15 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 癌関連タンパク質キナーゼ
CN107501407B (zh) * 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
NO2550972T3 (cg-RX-API-DMAC7.html) * 2007-04-02 2018-07-21
JP5187837B2 (ja) * 2007-04-06 2013-04-24 独立行政法人産業技術総合研究所 補助因子による受容体の活性化方法並びにリガンド活性の利用方法
US7537903B2 (en) * 2007-04-23 2009-05-26 Board Of Regents, The University Of Texas System FGF21 upregulates expression of GLUT-1 in a βklotho-dependent manner
EP2152295B1 (en) 2007-05-08 2018-04-18 Tel HaShomer Medical Research Infrastructure and Services Ltd. Klotho protein and related compounds for the treatment of cancer
EP2152737A2 (en) 2007-05-22 2010-02-17 Novartis Ag Methods of treating, diagnosing and detecting fgf21-associated disorders
JP5563818B2 (ja) 2007-05-29 2014-07-30 北海道公立大学法人 札幌医科大学 癌治療剤及び癌の治療方法
CN101778937A (zh) 2007-06-04 2010-07-14 诺和诺德公司 使用n-乙酰葡糖胺转移酶的o-联糖基化
US20110034373A1 (en) 2007-08-03 2011-02-10 Eli Lilly And Company Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
WO2009020602A2 (en) 2007-08-08 2009-02-12 Foster-Miller, Inc. Watercraft drogue system
US8426396B2 (en) 2008-01-08 2013-04-23 Shriners Hospitals For Children Treatment for achondroplasia
TW200936156A (en) * 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
US20110015345A1 (en) 2008-03-19 2011-01-20 Ambrx, Inc. Modified FGF-23 Polypeptides and Their Uses
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
WO2010006214A1 (en) 2008-07-09 2010-01-14 Ambrx, Inc. Fgf-21 neutralizing antibodies and their uses
EP2318529B1 (en) 2008-08-04 2017-10-18 Five Prime Therapeutics, Inc. Fgfr extracellular domain acidic region muteins
JP2012525847A (ja) * 2009-05-05 2012-10-25 アムジエン・インコーポレーテツド Ｆｇｆ２１変異体およびその使用
UY38740A (es) 2009-05-05 2020-12-31 Amgen Inc Mutantes de fgf21 y usos del mismo

Also Published As

Publication number Publication date
EP3248610B1 (en) 2023-12-20
AR076541A1 (es) 2011-06-22
CN102655877A (zh) 2012-09-05
SG175861A1 (en) 2011-12-29
TWI436776B (zh) 2014-05-11
EA021425B1 (ru) 2015-06-30
KR20120068764A (ko) 2012-06-27
KR101860572B1 (ko) 2018-05-24
SI3248610T1 (sl) 2024-03-29
CO6470863A2 (es) 2012-06-29
NZ596037A (en) 2013-10-25
JO3469B1 (ar) 2020-07-05
HK1247134A1 (en) 2018-09-21
HRP20240135T1 (hr) 2024-04-12
IL242377A (en) 2016-12-29
ES2632742T3 (es) 2017-09-15
DK3248610T3 (da) 2024-01-15
AU2010246108B2 (en) 2014-10-23
UY38740A (es) 2020-12-31
LT3248610T (lt) 2024-01-25
MY156542A (en) 2016-02-26
US20120177646A1 (en) 2012-07-12
PE20120358A1 (es) 2012-04-26
US8795985B2 (en) 2014-08-05
US20120213779A1 (en) 2012-08-23
US8188040B2 (en) 2012-05-29
BRPI1011404A2 (pt) 2016-03-15
EP4353247A2 (en) 2024-04-17
TW201446793A (zh) 2014-12-16
EP3248610A1 (en) 2017-11-29
FI3248610T3 (fi) 2024-01-18
SG10201402038WA (en) 2014-07-30
CL2011002768A1 (es) 2012-08-24
CN107188950A (zh) 2017-09-22
EP4353247A3 (en) 2024-07-17
CA2760196A1 (en) 2010-11-11
JP2012525844A (ja) 2012-10-25
UY32607A (es) 2010-12-31
TWI560197B (en) 2016-12-01
JP5823954B2 (ja) 2015-11-25
PH12015502433A1 (en) 2017-01-16
SMT202400036T1 (it) 2024-03-13
SG10201707763PA (en) 2017-11-29
PE20160718A1 (es) 2016-08-03
CN107188950B (zh) 2021-09-28
EP2427208A1 (en) 2012-03-14
DK3248610T5 (da) 2024-10-07
AU2010246108A1 (en) 2011-11-24
EA201171220A1 (ru) 2012-05-30
ZA201108371B (en) 2012-07-25
ES2969528T3 (es) 2024-05-21
CN102655877B (zh) 2017-04-05
EP2427208B1 (en) 2017-04-26
PH12015502433B1 (en) 2017-01-16
US20120178685A1 (en) 2012-07-12
HUE065036T2 (hu) 2024-04-28
CA2760196C (en) 2019-02-26
PT3248610T (pt) 2024-02-01
MX2011011709A (es) 2012-02-29
US20100285131A1 (en) 2010-11-11
IL215937A (en) 2015-11-30
KR20180014235A (ko) 2018-02-07
MA33716B1 (fr) 2012-11-01
TW201105345A (en) 2011-02-16
CR20110639A (es) 2012-01-06
IL215937A0 (en) 2011-12-29
US8618053B2 (en) 2013-12-31
US8835385B2 (en) 2014-09-16
RS65153B1 (sr) 2024-02-29
WO2010129503A1 (en) 2010-11-11
PL3248610T3 (pl) 2024-04-02

Similar Documents

Publication Publication Date Title
JP7191076B2 (ja) Ｆｇｆ２１突然変異体及びその使用
BRPI1011404B1 (pt) Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira
US9493530B2 (en) FGF21 mutants comprising a mutation at position 98, 171 and/or 180
HK40110187A (en) Fgf21 mutants and uses thereof
AU2014202582A1 (en) FGF21 mutants and uses thereof

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/05/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.